Clik here to view.
Tecnofarma to distribute Cipher’s tramadol
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has entered into a definitive distribution and supply agreement with Tecnofarma International, giving Tecnofarma the exclusive right to market, sell and...
View ArticleClik here to view.
Cipher posts record first quarter results
First quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) was $1.5-million or 6 cents a share on revenue of $3.3-million, compared with a profit of $125,000 or 1 cent on revenue of...
View ArticleClik here to view.
Cipher launches acne treatment in Canada
At the annual Canadian Dermatology Association Conference in Quebec City over the July 1 weekend, Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) announced the Canadian launch of Epuris, a novel brand...
View ArticleClik here to view.
Cipher posts big jump in Q2 revenue and profits
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported net income of $3.1-million or 13 cents a share on revenue of $5.5-million for the second quarter, compared with $200,000 or 1 cent on revenue...
View ArticleClik here to view.
Cipher Pharma Q3 profit jumps to $3.4-million
Third quarter net income for Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) rose to $3.4-million, or 14 cents a share, from $754,000, or 3 cents, in the year earlier quarter. Net revenue climbed to...
View ArticleClik here to view.
Cipher Pharma chairman to retire
William Garriock, chairman of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), is retiring from active business and has resigned as chairman, effective tomorrow. “On behalf of the board, i would like to...
View ArticleClik here to view.
Cipher posts record Q4 and full-year 2013 results
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has reported fourth quarter profit of $17-million or 69 cents a share, compared with $1.5-million or 6 cents in the 2012 quarter. Revenue rose to...
View ArticleClik here to view.
Larry Andrews steps down as Cipher Pharma head
Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). Larry Andrews To ensure a smooth transition of responsibilities, Mr. Andrews...
View ArticleClik here to view.
Cipher names Thomas Wellner to board
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Thomas Wellner to the board. Thomas Wellner Most recently, Mr. Wellner was co-CEO of LifeLabs, Canada’s largest laboratory services company,...
View ArticleClik here to view.
Cipher Pharma names Shawn O’Brien as CEO
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has named Shawn O’Brien as CEO, effective June 30, succeeding Larry Andrews, who announced in March that he was stepping down. Mr. O’Brien has spent the...
View ArticleClik here to view.
Cipher partner launches Absorica in U.S.
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) announced that its partner, Ranbaxy Laboratories, has begun the sales and promotion of Absorica, Cipher’s novel, patented, brand formulation of the acne...
View ArticleClik here to view.
Cipher reports record financial results for 2012
Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) has reported net income of $2.5-million, or 10 cents share, for 2012, compared with a year earlier loss of $2.3-million. Revenue soared 137% to...
View ArticleClik here to view.
Health Canada clears Cipher acne medicine
Cipher Pharmaceuticals (TSX:DND) has received approval from Health Canada for its new drug submission for Epuris, a novel, brand formulation of the acne medication isotretinoin for the treatment of...
View ArticleClik here to view.
Cipher Pharma chairman to retire
William Garriock, chairman of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), is retiring from active business and has resigned as chairman, effective tomorrow. “On behalf of the board, i would like to...
View ArticleClik here to view.
Cipher Pharma names Shawn O’Brien as CEO
Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has named Shawn O’Brien as CEO, effective June 30, succeeding Larry Andrews, who announced in March that he was stepping down. Mr. O’Brien has spent the...
View ArticleClik here to view.
Cipher gets sales milestone for Lipofen
Cipher Pharmaceuticals‘ (TSX:DND) Lipofen fenofibrate product reached a cumulative sales milestone, triggering a $1 million (U.S.) milestone payment from Kowa Pharmaceuticals America, Cipher’s U.S....
View ArticleClik here to view.
Cipher gets U.S. patent for tramadol
The U.S. Patent and Trademark Office has issued a patent notice of allowance for Cipher Pharmaceuticals’ (TSX:DND) CIP-Tramadol ER, an extended-release product for the treatment of moderate to...
View ArticleClik here to view.
Cipher completes CIP-Isotretinoin enrolment
Cipher Pharmaceuticals (TSX:DND) has completed patient enrolment in a Phase 3 safety study of its CIP-Isotretinoin treatment of severe, nodular acne. A total of 931 patients were enrolled in the trial,...
View ArticleClik here to view.
Vertical Pharma to distribute Cipher’s tramadol in U.S.
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Vertical Pharmaceuticals to market Cipher’s CIP-TRAMADOL ER in the U.S. for the treatment of moderate to...
View ArticleClik here to view.
Cipher signs up Canadian distributor for Tramadol
Cipher Pharmaceuticals (TSX:DND) has entered into a distribution and supply agreement with Medical Futures, a closely held Canadian pharmaceutical company, for the marketing of Durela in Canada. Durela...
View Article